solo para uso en investigación
Cat. No.: S4260
| Dianas relacionadas | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Otros Retinoid Receptor Inhibidores | TTNPB (Arotinoid acid) AM580 Fenretinide UVI 3003 SR 11237 BMS493 AR7 All trans-Retinal MSU-42011 Palovarotene |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| NB4 cells | Proliferation assay | 48 h | Antiproliferative activity against human NB4 cells after 48 hrs by MTT assay, IC50=4.81 μM | |||
| HL60 cells | Proliferation assay | Antiproliferative activity against human HL60 cells, IC50=6 μM | ||||
| HL60 cells | Proliferation assay | 48 h | Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay, IC50=8.94 μM | |||
| Jurkat cells | Proliferation assay | Antiproliferative activity against human Jurkat cells, IC50=17.3 μM | ||||
| MOLT4 cells | Proliferation assay | Antiproliferative activity against human MOLT4 cells, IC50=19.5 μM | ||||
| U937 cells | Proliferation assay | Antiproliferative activity against human U937 cells, IC50=20.2 μM | ||||
| K562 cells | Proliferation assay | 48 h | Antiproliferative activity against human K562 cells after 48 hrs by MTT assay, IC50=42.37 μM | |||
| COS-1 cells | Function assay | Transcriptional activation in COS-1 cells expressing Retinoic Acid Receptor alpha (RAR alpha) | ||||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 351.44 | Fórmula | C22H25NO3 |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 94497-51-5 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | Am 80 | Smiles | CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C | ||
|
In vitro |
DMSO
: 70 mg/mL
(199.18 mM)
Ethanol : 70 mg/mL Water : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
RARα
RARβ
|
|---|---|
| In vitro |
Tamibarotene slightly inhibits the growth of both myeloma cells and HUVECs, and remarkably inhibits the growth of HUVECs stimulated by VEGF. This compound shows little growth inhibition of bone marrow stromal cells (BMSCs), but it markedly inhibits migration of HUVECs by cocultured myeloma cells. It inhibits VEGF-induced phosphorylation of VEGF receptor. The compound significantly inhibits VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas. This chemical-induced HL-60 cell adhesion to ECs is 38% lower than All-trans retinoic acid (ATRA), and NB4 cell adhesion to ECs by this compound is equivalent to ATRA, which induces CD38 gene transcription biphasically in HL-60 cells, the early-phase induction via DR-RARE containing intron 1, and the delayed-phase induction via RARE lacking the 5'-flanking region. It induces only the early-phase induction in HL-60 cells, resulting in its lower CD38 induction than ATRA. This agent has negligible growth inhibition of peripheral blood mononuclear cells but marked growth inhibition of both HTLV-I-infected T-cell lines and ATL cells. It arrests cells in the G1 phase of the cell cycle and induces apoptosis in HTLV-I-infected T-cell lines. The compound inhibits also the phosphorylation of IkappaBalpha and NF-kappaB-DNA binding, in conjunction with reduction of expression of proteins involved in the G1/S cell cycle transition and apoptosis. It also inhibits the expression of JunD, resulting in suppression of AP-1-DNA binding. |
| In vivo |
Tamibarotene treatment reduces significantly the insoluble Abeta levels in brain of mice, in particular Abeta(42), while it gives no apparent effects on the soluble Abeta levels. |
Referencias |
|
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT04905407 | Recruiting | Acute Myeloid Leukemia |
Syros Pharmaceuticals |
August 26 2021 | Phase 2 |
| NCT02807558 | Completed | Acute Myeloid Leukemia|Myelodysplastic Syndrome |
Syros Pharmaceuticals |
September 20 2016 | Phase 2 |
| NCT00985530 | Terminated | Acute Promyelocytic Leukemia |
Northwestern University|CytRx|Cephalon |
October 2009 | Phase 1 |
| NCT00520208 | Completed | Acute Promyelocytic Leukemia |
CytRx |
September 2007 | Phase 2 |